Nothing Special   »   [go: up one dir, main page]

FR2873925B1 - Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes - Google Patents

Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes

Info

Publication number
FR2873925B1
FR2873925B1 FR0408667A FR0408667A FR2873925B1 FR 2873925 B1 FR2873925 B1 FR 2873925B1 FR 0408667 A FR0408667 A FR 0408667A FR 0408667 A FR0408667 A FR 0408667A FR 2873925 B1 FR2873925 B1 FR 2873925B1
Authority
FR
France
Prior art keywords
erythrocytes
lysis
suspension
rescaling
lyse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0408667A
Other languages
English (en)
Other versions
FR2873925A1 (fr
Inventor
Yann Godfrin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phaxiam Therapeutics SA
Original Assignee
Erytech Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34949346&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2873925(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Erytech Pharma SA filed Critical Erytech Pharma SA
Priority to FR0408667A priority Critical patent/FR2873925B1/fr
Priority to JP2007524421A priority patent/JP4598827B2/ja
Priority to SI200531459T priority patent/SI1773452T1/sl
Priority to AT05768180T priority patent/ATE532504T1/de
Priority to CN2005800298147A priority patent/CN101031339B/zh
Priority to US11/573,093 priority patent/US8617840B2/en
Priority to ES05768180T priority patent/ES2376979T3/es
Priority to EP05768180A priority patent/EP1773452B1/fr
Priority to PT05768180T priority patent/PT1773452E/pt
Priority to PL05768180T priority patent/PL1773452T3/pl
Priority to PCT/IB2005/002323 priority patent/WO2006016247A2/fr
Priority to DK05768180.1T priority patent/DK1773452T3/da
Priority to CA2892729A priority patent/CA2892729C/fr
Priority to KR1020077004994A priority patent/KR101332733B1/ko
Priority to CA2575617A priority patent/CA2575617C/fr
Priority to AU2005270977A priority patent/AU2005270977B2/en
Priority to EP10183315.0A priority patent/EP2277594B1/fr
Publication of FR2873925A1 publication Critical patent/FR2873925A1/fr
Publication of FR2873925B1 publication Critical patent/FR2873925B1/fr
Application granted granted Critical
Priority to HK08101485.2A priority patent/HK1110030A1/xx
Priority to US14/089,834 priority patent/US10273444B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/06—Hydrolysis; Cell lysis; Extraction of intracellular or cell wall material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Sustainable Development (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0408667A 2004-08-05 2004-08-05 Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes Expired - Lifetime FR2873925B1 (fr)

Priority Applications (19)

Application Number Priority Date Filing Date Title
FR0408667A FR2873925B1 (fr) 2004-08-05 2004-08-05 Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes
PCT/IB2005/002323 WO2006016247A2 (fr) 2004-08-05 2005-08-04 Procede de lyse/rescellement et dispositif permettant d'incorporer un ingredient actif, en particulier de l'asparaginase ou de l'inositol hexaphosphate, dans des globules rouges
CA2892729A CA2892729C (fr) 2004-08-05 2005-08-04 Procede de lyse/rescellement et dispositif permettant d'incorporer un ingredient actif, en particulier de l'asparaginase ou de l'inositol hexaphosphate, dans des globules rouges
AT05768180T ATE532504T1 (de) 2004-08-05 2005-08-04 Lyse / wiederverschlussverfahren zum einbau eines wirkstoffs in erythrozyten
CN2005800298147A CN101031339B (zh) 2004-08-05 2005-08-04 将活性成份掺入红细胞的裂解/再封方法和装置
US11/573,093 US8617840B2 (en) 2004-08-05 2005-08-04 Lysis/resealing process and device for incorporating an active ingredient, in particular asparaginase or inositol hexaphosphate, in erythrocytes
ES05768180T ES2376979T3 (es) 2004-08-05 2005-08-04 Procedimiento de lisis/resellado para incorporar un ingrediente activo en eritrocitos
EP05768180A EP1773452B1 (fr) 2004-08-05 2005-08-04 Procede de lyse/rescellement permettant d'incorporer un ingredient actif dans des globules rouges
PT05768180T PT1773452E (pt) 2004-08-05 2005-08-04 Processo de lise/resselagem e dispositivo para incorporar um ingrediente activo em eritrócitos
PL05768180T PL1773452T3 (pl) 2004-08-05 2005-08-04 Proces lizy/ponownego zamykania do wprowadzania substancji czynnej do erytrocytów
JP2007524421A JP4598827B2 (ja) 2004-08-05 2005-08-04 活性成分、特にアスパラギナーゼまたはイノシトールヘキサホスフェートを赤血球中に組み込むための溶解／再シーリング方法及び装置
DK05768180.1T DK1773452T3 (da) 2004-08-05 2005-08-04 Fremgangsmåde til lysis/genlukning med henblik på inkorporering af et aktivt stof i erythrocytter
SI200531459T SI1773452T1 (sl) 2004-08-05 2005-08-04 Postopek lizis resealing uvajanja učinkovine v eritrocite
KR1020077004994A KR101332733B1 (ko) 2004-08-05 2005-08-04 적혈구에 활성 성분을 내재화시키는 용해/재봉합 방법 및 장치
CA2575617A CA2575617C (fr) 2004-08-05 2005-08-04 Procede de lyse/rescellement et dispositif permettant d'incorporer un ingredient actif, en particulier de l'asparaginase ou de l'inositol hexaphosphate, dans des globules rouges
AU2005270977A AU2005270977B2 (en) 2004-08-05 2005-08-04 Lysis/resealing process and device for incorporating an active ingredient in erythrocytes
EP10183315.0A EP2277594B1 (fr) 2004-08-05 2005-08-04 Procédé et dispositif de lyse-rescellement pour l'incorporation de principe actif dans des érythrocytes
HK08101485.2A HK1110030A1 (en) 2004-08-05 2008-02-06 Lysis/resealing process and device for incorporating an active ingredient in erythrocytes
US14/089,834 US10273444B2 (en) 2004-08-05 2013-11-26 Lysis/resealing process and device for incorporating an active ingredient, in particular asparaginase or inositol hexaphosphate, in erythrocytes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0408667A FR2873925B1 (fr) 2004-08-05 2004-08-05 Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes

Publications (2)

Publication Number Publication Date
FR2873925A1 FR2873925A1 (fr) 2006-02-10
FR2873925B1 true FR2873925B1 (fr) 2006-10-13

Family

ID=34949346

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0408667A Expired - Lifetime FR2873925B1 (fr) 2004-08-05 2004-08-05 Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes

Country Status (16)

Country Link
US (2) US8617840B2 (fr)
EP (2) EP2277594B1 (fr)
JP (1) JP4598827B2 (fr)
KR (1) KR101332733B1 (fr)
CN (1) CN101031339B (fr)
AT (1) ATE532504T1 (fr)
AU (1) AU2005270977B2 (fr)
CA (2) CA2892729C (fr)
DK (1) DK1773452T3 (fr)
ES (1) ES2376979T3 (fr)
FR (1) FR2873925B1 (fr)
HK (1) HK1110030A1 (fr)
PL (1) PL1773452T3 (fr)
PT (1) PT1773452E (fr)
SI (1) SI1773452T1 (fr)
WO (1) WO2006016247A2 (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986944B2 (en) 2001-10-11 2015-03-24 Aviva Biosciences Corporation Methods and compositions for separating rare cells from fluid samples
US8980568B2 (en) 2001-10-11 2015-03-17 Aviva Biosciences Corporation Methods and compositions for detecting non-hematopoietic cells from a blood sample
FR2891843A1 (fr) * 2005-10-06 2007-04-13 Erytech Pharma Soc Par Actions Erythrocytes contenant du 5-fluorouracile
WO2008008515A2 (fr) 2006-07-14 2008-01-17 Aviva Biosciences Corporation Procédés et compositions servant à détecter des cellules rares dans un échantillon biologique
KR100828018B1 (ko) * 2006-11-20 2008-05-08 레인보우스케이프주식회사 수질정화용 여과재
AU2008241388B2 (en) * 2007-04-20 2013-04-04 Purdue Research Foundation Methods for counting cells
FR2919804B1 (fr) 2007-08-08 2010-08-27 Erytech Pharma Composition et vaccin therapeutique anti-tumoral
FR2925339B1 (fr) * 2007-12-24 2010-03-05 Erytech Pharma Medicament pour le traitement du cancer du pancreas
ES2405258T3 (es) * 2008-02-13 2013-05-30 Erytech Pharma Formulación y procedimiento para la prevención y el tratamiento de la manifestación esquelética de la enfermedad de Gaucher
FR2938332B1 (fr) * 2008-11-07 2011-11-25 Erytech Pharma Test predictif de la neutralisation de l'activite asparaginase
FR2940087B1 (fr) * 2008-12-18 2011-05-06 Lab Francais Du Fractionnement Erythrocytes contenant du facteur viii, preparation et utilisations.
EP2199791B1 (fr) * 2008-12-19 2019-05-01 F. Hoffmann-La Roche AG Méthode pour evaluer l'hémolyse dans les érythrocytes et dispositif associé
FR2944106B1 (fr) 2009-04-03 2012-09-28 Erytech Pharma Methode de dosage de l'inositol hexaphosphate (ihp).
CA2778669C (fr) * 2009-10-27 2019-04-16 Erytech Pharma Composition induisant une tolerance immunitaire specifique
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
AU2011289579B2 (en) 2010-08-10 2016-11-17 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
WO2013019290A2 (fr) * 2011-04-21 2013-02-07 Streck, Inc. Témoin de référence pour fraction de réticulocytes immatures et procédé apparentés
CA2867662A1 (fr) 2012-03-21 2013-09-26 Erytech Pharma Medicament pour le traitement de la leucemie myeloide aigue (aml)
FR3005420B1 (fr) * 2013-05-07 2015-09-18 Erytech Pharma Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues.
ES2950419T3 (es) * 2013-05-10 2023-10-09 Erydel Spa Procedimiento para la preparación de eritrocitos cargados con una o más sustancias de interés farmacéutico y eritrocitos obtenidos de esta manera
EP2813234A1 (fr) 2013-06-11 2014-12-17 Erytech Pharma Composition d'érythrocytes encapsulant phenylalanine hydroxylase et l'emploi thérapeutique
SG11201601927SA (en) 2013-08-16 2016-04-28 Massachusetts Inst Technology Selective delivery of material to cells
CA2930665A1 (fr) 2013-11-18 2015-05-21 Rubius Therapeutics, Inc. Complexes membrane synthetique- recepteur
FR3017299B1 (fr) * 2014-02-12 2018-05-18 Erytech Pharma Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
SG11201606761RA (en) 2014-02-21 2016-09-29 Ecole Polytecnique Federale De Lausanne Epfl Epfl Tto Glycotargeting therapeutics
CA2944492A1 (fr) 2014-04-01 2015-10-08 Rubius Therapeutics, Inc. Methodes et compositions d'immunomodulation
WO2016070136A1 (fr) 2014-10-31 2016-05-06 Massachusetts Institute Of Technology Administration de biomolécules en direction de cellules du système immunitaire
EP3245294A4 (fr) 2015-01-12 2018-05-30 Massachusetts Institute of Technology Édition de gène par administration microfluidique
CA2988996A1 (fr) * 2015-07-09 2017-01-12 Massachusetts Institute Of Technology Administration de substances a des cellules anucleees
WO2017041051A1 (fr) 2015-09-04 2017-03-09 Sqz Biotechnologies Company Administration intracellulaire de biomolécules à des cellules comprenant une paroi cellulaire
EP3187190A1 (fr) 2015-12-31 2017-07-05 Erytech Pharma Procédé de traitement d'un mammifère, y compris l'être humain, contre le cancer au moyen de la méthionine et la déplétion de l'asparagine
SG11201805442XA (en) 2016-01-11 2018-07-30 Rubius Therapeutics Inc Compositions and methods related to multimodal therapeutic cell systems for immune indications
RU2770492C2 (ru) * 2016-05-03 2022-04-18 ЭсКьюЗед БАЙОТЕКНОЛОДЖИЗ КОМПАНИ Внутриклеточная доставка биологических молекул для индуцирования толерантности
ES2909556T3 (es) 2016-08-08 2022-05-09 Aerase Inc Composiciones y procedimientos para el tratamiento de cáncer con agentes de disminución de arginina y de inmunoncología
EP3638296A1 (fr) 2017-06-16 2020-04-22 The University Of Chicago Compositions et procédés d'induction d'une tolérance immunitaire
EP3449935A1 (fr) 2017-08-31 2019-03-06 Erytech Pharma Arginine deiminase encapsulée à l'intérieur des érythrocytes et leur utilisation dans le traitement du cancer et de la déficience en arginase-1
WO2019042628A1 (fr) 2017-08-31 2019-03-07 Erytech Pharma Arginine déiminase encapsulée à l'intérieur d'érythrocytes et leur utilisation dans le traitement du cancer et d'une déficience en arginase-1
CN111787941A (zh) 2017-12-05 2020-10-16 艾瑞思有限公司 用于治疗精氨酸酶1缺乏症的方法和组合物
US20210299233A1 (en) 2018-07-12 2021-09-30 The Children's Medical Center Corporation Method for treating cancer
CA3111126A1 (fr) 2018-08-31 2020-03-05 Stichting Katholieke Universiteit Combinaisons synergiques de sensibilisateurs d'agent de depletion en acides amines (aadas) et d'agents de depletion en acides amines (aada), et leurs procedes therapeutiques d'uti lisation
WO2020099592A1 (fr) 2018-11-15 2020-05-22 Erytech Pharma Combinaisons synergiques d'agents de déplétion de méthionine et de modulateurs de points de contrôle immunitaires
WO2020202149A1 (fr) * 2019-04-01 2020-10-08 Given Imaging Ltd. Système d'immunodosage in vivo
AU2021270347A1 (en) 2020-05-11 2022-12-15 Erytech Pharma Red cell extracellular vesicles (RCEVs) containing cargoes and methods of use and production thereof
US20220313798A1 (en) 2021-03-30 2022-10-06 Jazz Pharmaceuticals Ireland Ltd. Dosing of recombinant l-asparaginase
WO2023027613A1 (fr) * 2021-08-27 2023-03-02 Общество С Ограниченной Ответственностью "Рбк-Фармэко" Dispositif et procédé pour inclure des composants bio-actifs dans des érythrocytes selon un procédé de dialyse continue
WO2023067200A1 (fr) 2021-10-24 2023-04-27 Erytech Pharma Asparaginase encapsulée dans des globules rouges pour le traitement du cancer du pancréas
WO2024015529A2 (fr) 2022-07-14 2024-01-18 Jazz Pharmaceuticals Ireland Ltd. Polythérapies impliquant la l-asparaginase

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2740053A1 (de) 1977-09-06 1979-05-03 Klaus Prof Dr Med Gersonde Verwendung von allosterischen effektoren mit hilfe von lipidvesikeln ueber eine irreversible inkorporierung zwecks verbesserter o tief 2 -entladung des haemoglobins in erythrozyten
JPS5468291A (en) * 1977-11-10 1979-06-01 Mitsubishi Chem Ind Method of measuring osmotic pressure resistance of corpuscle membrane
US4327710A (en) * 1980-06-18 1982-05-04 The United States Of America As Represented By The Secretary Of Agriculture Process for encapsulating additives in resealed erythrocytes for disseminating chemicals via the circulatory system
FR2529463B1 (fr) 1982-07-05 1986-01-10 Centre Nat Rech Scient Procede et dispositif pour l'encapsulation dans les erythrocytes d'au moins une substance a activite biologique, notamment des effecteurs allosteriques de l'hemoglobine et erythrocytes ainsi obtenus
US4478824A (en) 1983-08-08 1984-10-23 Franco Robert S Method for altering red blood cell function and survival
US4801777A (en) * 1987-09-03 1989-01-31 Vanderbilt University Blood rewarming method and apparatus
FR2678512B1 (fr) 1991-07-03 1995-06-30 Novacell Machine a internaliser.
WO1994021117A1 (fr) * 1993-03-23 1994-09-29 Cbr Laboratories, Inc. Methode et appareil d'encapsulation de substances biologiquement actives dans des cellules
DE69732225T2 (de) 1997-05-05 2005-06-23 Dideco S.R.L., Mirandola Verfahren zur Verkapselung von biologisch aktiven Stoffen in Erythrocyten und Gerät dafür
AU2001279118A1 (en) 2000-08-01 2002-02-13 Gmp Companies, Inc. Ammonium salts of inositol hexaphosphate and uses thereof

Also Published As

Publication number Publication date
EP1773452A2 (fr) 2007-04-18
CA2575617C (fr) 2015-10-06
HK1110030A1 (en) 2008-07-04
CA2892729A1 (fr) 2006-02-16
ES2376979T3 (es) 2012-03-21
US20140154797A1 (en) 2014-06-05
CN101031339B (zh) 2012-07-18
CA2892729C (fr) 2017-05-09
AU2005270977B2 (en) 2011-11-24
JP2008508920A (ja) 2008-03-27
WO2006016247A3 (fr) 2006-06-22
CA2575617A1 (fr) 2006-02-16
ATE532504T1 (de) 2011-11-15
EP2277594A3 (fr) 2011-05-18
US8617840B2 (en) 2013-12-31
DK1773452T3 (da) 2012-02-27
PT1773452E (pt) 2012-02-08
KR20070058478A (ko) 2007-06-08
PL1773452T3 (pl) 2012-04-30
US20080261262A1 (en) 2008-10-23
CN101031339A (zh) 2007-09-05
KR101332733B1 (ko) 2013-11-25
US10273444B2 (en) 2019-04-30
AU2005270977A1 (en) 2006-02-16
WO2006016247A2 (fr) 2006-02-16
EP2277594A2 (fr) 2011-01-26
FR2873925A1 (fr) 2006-02-10
EP2277594B1 (fr) 2016-03-30
JP4598827B2 (ja) 2010-12-15
SI1773452T1 (sl) 2012-03-30
EP1773452B1 (fr) 2011-11-09

Similar Documents

Publication Publication Date Title
FR2873925B1 (fr) Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes
US11806431B2 (en) Formulations and methods for contemporaneous stabilization of active proteins during spray drying and storage
Kundu et al. Effect of amino acids on goat cauda epididymal sperm cryopreservation using a chemically defined model system
Reddoch et al. Hemostatic function of apheresis platelets stored at 4 C and 22 C
JP5138372B2 (ja) 凍結乾燥血小板の調製法、凍結乾燥血小板を含む組成物、および使用法
US20160030532A1 (en) Erythrocytes containing arginine deiminase
Reikvam et al. The Mirasol® Pathogen Reduction Technology system and quality of platelets stored in platelet additive solution
Makley et al. Murine blood banking: characterization and comparisons to human blood
Noulsri et al. Effects of donor age, donor sex, blood-component processing, and storage on cell-derived microparticle concentrations in routine blood-component preparation
Swami et al. Cysteamine supplementation revealed detrimental effect on cryosurvival of buffalo sperm based on computer-assisted semen analysis and oxidative parameters
EP2903432A1 (fr) Procédés de traitement de sperme pour un tri par sexe
US11589575B2 (en) Injectable preserving medium for preserving cells from placental blood, from bone marrow and from peripheral blood
Ghorbani et al. The antioxidant roles of L-carnitine and N-acetyl cysteine against oxidative stress on human sperm functional parameters during vitrification
Grau et al. Decrease in red blood cell deformability is associated with a reduction in RBC-NOS activation during storage
Rajashekaraiah et al. Platelet storage: Progress so far
Yamashiro et al. Lactate and adenosine triphosphate in the extender enhance the cryosurvival of rat epididymal sperm
Barshtein et al. Preparation of packed red blood cell units in the blood bank: Alteration in red blood cell deformability
Martins et al. Milk, caseinate and lactoferrin addition to equine semen cooling extenders
Arav et al. Freeze drying (lyophilization) of red blood cells
US11279913B2 (en) Sperm processing method, apparatus and related media compositions
US20160081328A1 (en) Solutions for Red Blood Cells
CN108018260A (zh) 用于多种细胞因子诱导的杀伤细胞的冷冻复苏液及其应用
Anel‐López et al. The effect of oxidative stress on thawed bulk‐sorted red deer sperm
WO2011089391A1 (fr) Procédés de conservation de cellules de mammifère
Ma et al. Effect of glycerol addition time on the cryopreserved Korean native brindle cattle (Chikso) sperm quality

Legal Events

Date Code Title Description
AU Other action affecting the ownership or exploitation of an industrial property right
CA Change of address
PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20